| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8647296 | Multiple Sclerosis and Related Disorders | 2018 | 8 Pages |
Abstract
- Glucocorticosteroid (GCS) continuous to decrease in Germany.
- Natalizumab utilization decreased with the emergence of additional treatment options.
- GCS utilization decreases for both RRMS and SPMS.
- The generally observed decrease in relapses per year is confirmed with in the data.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
David Ellenberger, Kerstin Eichstädt, Peter Flachenecker, Tim Friede, Judith Haas, Christoph Kleinschnitz, Dieter Pöhlau, Otto Rienhoff, Alexander Stahmann, Uwe K Zettl, Paulus S Rommer,